226 related articles for article (PubMed ID: 16762150)
21. Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity.
Sakthiswary R; Rajalingam S; Hussein H; Sridharan R; Asrul AW
Clin Rheumatol; 2017 Dec; 36(12):2683-2688. PubMed ID: 28889184
[TBL] [Abstract][Full Text] [Related]
22. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis.
Happonen KE; Saxne T; Aspberg A; Mörgelin M; Heinegård D; Blom AM
Arthritis Rheum; 2010 Dec; 62(12):3574-83. PubMed ID: 20737467
[TBL] [Abstract][Full Text] [Related]
23. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts.
Dodge GR; Hawkins D; Boesler E; Sakai L; Jimenez SA
Osteoarthritis Cartilage; 1998 Nov; 6(6):435-40. PubMed ID: 10343777
[TBL] [Abstract][Full Text] [Related]
24. Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis.
Mânsson B; Gülfe A; Geborek P; Heinegård D; Saxne T
Ann Rheum Dis; 2001 Jan; 60(1):27-31. PubMed ID: 11114278
[TBL] [Abstract][Full Text] [Related]
25. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis.
O'Hara R; Murphy EP; Whitehead AS; FitzGerald O; Bresnihan B
Arthritis Rheum; 2004 Jun; 50(6):1788-99. PubMed ID: 15188355
[TBL] [Abstract][Full Text] [Related]
26. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
27. [An antidestructive effect of leflunomide in early rheumatoid arthritis].
Balabanova RM; Kashevarov RIu; Oliunin IuA; Smirnov AV; Aleksandrova EN
Ter Arkh; 2006; 78(6):6-10. PubMed ID: 16881355
[TBL] [Abstract][Full Text] [Related]
28. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein.
Senolt L; Braun M; Olejárová M; Forejtová S; Gatterová J; Pavelka K
Ann Rheum Dis; 2005 Jun; 64(6):886-90. PubMed ID: 15897309
[TBL] [Abstract][Full Text] [Related]
29. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
[TBL] [Abstract][Full Text] [Related]
30. [Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP].
Yamamoto M; Takahashi H; Ohara M; Suzuki C; Naishiro Y; Yamamoto H; Shinomura Y; Imai K
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Feb; 30(1):41-7. PubMed ID: 17332704
[TBL] [Abstract][Full Text] [Related]
31. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis.
Forslind K; Eberhardt K; Jonsson A; Saxne T
Br J Rheumatol; 1992 Sep; 31(9):593-8. PubMed ID: 1525624
[TBL] [Abstract][Full Text] [Related]
32. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
[TBL] [Abstract][Full Text] [Related]
33. Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids.
Hummel KM; Neidhart M; Vilim V; Hauser N; Aicher WK; Gay RE; Gay S; Häuselmann HJ
Br J Rheumatol; 1998 Jul; 37(7):721-8. PubMed ID: 9714346
[TBL] [Abstract][Full Text] [Related]
34. Deformational behaviour of knee cartilage and changes in serum cartilage oligomeric matrix protein (COMP) after running and drop landing.
Niehoff A; Müller M; Brüggemann L; Savage T; Zaucke F; Eckstein F; Müller-Lung U; Brüggemann GP
Osteoarthritis Cartilage; 2011 Aug; 19(8):1003-10. PubMed ID: 21616158
[TBL] [Abstract][Full Text] [Related]
35. Effects of moving training on histology and biomarkers levels of articular cartilage.
Qi C; Changlin H
J Surg Res; 2006 Oct; 135(2):352-63. PubMed ID: 16904690
[TBL] [Abstract][Full Text] [Related]
36. Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids.
Misumi K; Vilim V; Clegg PD; Thompson CC; Carter SD
Osteoarthritis Cartilage; 2001 Feb; 9(2):119-27. PubMed ID: 11237659
[TBL] [Abstract][Full Text] [Related]
37. Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein.
Guo F; Lai Y; Tian Q; Lin EA; Kong L; Liu C
Arthritis Rheum; 2010 Jul; 62(7):2023-36. PubMed ID: 20506400
[TBL] [Abstract][Full Text] [Related]
38. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
Crnkic M; Månsson B; Larsson L; Geborek P; Heinegård D; Saxne T
Arthritis Res Ther; 2003; 5(4):R181-5. PubMed ID: 12823852
[TBL] [Abstract][Full Text] [Related]
39. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
[TBL] [Abstract][Full Text] [Related]
40. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein.
Liu CJ; Kong W; Ilalov K; Yu S; Xu K; Prazak L; Fajardo M; Sehgal B; Di Cesare PE
FASEB J; 2006 May; 20(7):988-90. PubMed ID: 16585064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
